Q-linea AB (publ) risk profile
98 Acute at or past the historical limit
Measured 10 September 2026 from 3F80's filed statements. Recomputed nightly.
98 (Acute), driven by Cash conversion at 100, over 3 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 89 | Acute | Stable | Drawdown from the 52-week high — 63.9% |
| Operating pressure | Reads cost_of_revenue, operating_expense, operating_income and revenue. No reading is stored for this company. | |||
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.03x |
| Leverage and coverage | Reads total_debt, cash_and_cash_equivalents, ebitda, interest_expense, total_current_assets, total_current_liabilities and a disclosed CET1 ratio, for a bank or insurer. No reading is stored for this company. | |||
| Competitive position | 100 | Acute | Stable | Operating-margin gap against peers — -8,938.8 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 34Johnson & Johnson 39Abbvie Inc 58Roche Holding AG 36Merck & Co Inc 35Unitedhealth Group Inc 49Novartis AG 30Astrazeneca plc 33Thermo Fisher Scientific Inc 47AMGEN Inc 47Novo Nordisk A/S 23Abbott Laboratories 37
Financials, valuation and price history for Q-linea AB (publ)